Global Anti-depressant Drugs Market Research Report 2021

Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive–compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraine, attention-deficit hyperactivity disorder (ADHD), addiction, dependence, and sleep disorders. They may be prescribed alone or in combination with other medications.
Anti-depressant Drugs Market by Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others) and Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others)

The global Anti-depressant Drugs market was valued at US$ 12230 million in 2020 and is expected to reach US$ 13890 million by the end of 2027, growing at a CAGR of 2.6% during 2021-2027.
This report focuses on Anti-depressant Drugs volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Anti-depressant Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Anti-depressant Drugs Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
Selective Serotonin Reuptake Inhibitor (SSRI)
Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Tricyclic Antidepressant (TCA)
Monoamine Oxidase Inhibitor (MAOI)
Others

Segment by Application
Major Depressive Disorder
Obsessive-Compulsive Disorder
Generalized Anxiety Disorder
Panic Disorder
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
Alkermes
Allergan
Bristol-Myers Squibb
Eli Lilly and Company
GlaxoSmithKline
Lundbeck
Merck
Pfizer
Teva Pharmaceutical Industries
Takeda Pharmaceutical Company
AstraZeneca
Johnson and Johnson
Sanofi
Sun Pharmaceuticals